Publications
Found 2 results
Filters: Author is T. Aoki [Clear All Filters]
“GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer”, vol. 9, pp. 1045-1053, 2010.
, Adler V, Yin Z, Fuchs SY, Benezra M, et al. (1999). Regulation of JNK signaling by GSTp. EMBO J. 18: 1321-1334.
http://dx.doi.org/10.1093/emboj/18.5.1321
PMid:10064598 PMCid:1171222
Allan JM, Wild CP, Rollinson S, Willett EV, et al. (2001). Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl. Acad. Sci. U. S. A. 98: 11592-11597.
http://dx.doi.org/10.1073/pnas.191211198
PMid:11553769 PMCid:58774
Alpert LC, Schecter RL, Berry DA, Melnychuk D, et al. (1997). Relation of glutathione S-transferase alpha and mu isoforms to response to therapy in human breast cancer. Clin. Cancer Res. 3: 661-667.
PMid:9815734
Ambrosone CB, Sweeney C, Coles BF, Thompson PA, et al. (2001). Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res. 61: 7130-7135.
PMid:11585745
Arrick BA and Nathan CF (1984). Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 44: 4224-4232.
PMid:6380705
Burg D and Mulder GJ (2002). Glutathione conjugates and their synthetic derivatives as inhibitors of glutathione-dependent enzymes involved in cancer and drug resistance. Drug Metab. Rev. 34: 821-863.
http://dx.doi.org/10.1081/DMR-120015695
PMid:12487151
Cho SG, Lee YH, Park HS, Ryoo K, et al. (2001). Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1. J. Biol. Chem. 276: 12749-12755.
http://dx.doi.org/10.1074/jbc.M005561200
PMid:11278289
Daly AK (2003). Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol. 17: 27-41.
http://dx.doi.org/10.1046/j.1472-8206.2003.00119.x
PMid:12588628
Dang DT, Chen F, Kohli M, Rago C, et al. (2005). Glutathione S-transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Res. 65: 9485-9494.
http://dx.doi.org/10.1158/0008-5472.CAN-05-1930
PMid:16230413
Dirven HA, van Ommen B and van Bladeren PJ (1994). Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res. 54: 6215-6220.
PMid:7954469
Hamada S, Kamada M, Furumoto H, Hirao T, et al. (1994). Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol. Oncol. 52: 313-319.
http://dx.doi.org/10.1006/gyno.1994.1055
PMid:8157188
Hayes JD and Pulford DJ (1995). The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30: 445-600.
http://dx.doi.org/10.3109/10409239509083491
PMid:8770536
Howells RE, Holland T, Dhar KK, Redman CW, et al. (2001). Glutathione S-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival. Int. J. Gynecol. Cancer 11: 107-112.
http://dx.doi.org/10.1046/j.1525-1438.2001.011002107.x
PMid:11328408
Huang J, Tan PH, Thiyagarajan J and Bay BH (2003). Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod. Pathol. 16: 558-565.
http://dx.doi.org/10.1097/01.MP.0000071842.83169.5A
PMid:12808061
Khedhaier A, Remadi S, Corbex M, Ahmed SB, et al. (2003). Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma. Br. J. Cancer 89: 1502-1507.
http://dx.doi.org/10.1038/sj.bjc.6601292
PMid:14562023 PMCid:2394332
L'Ecuyer T, Allebban Z, Thomas R and Vander Heide R (2004). Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. Am. J. Physiol. Heart Circ. Physiol. 286: H2057-2064.
http://dx.doi.org/10.1152/ajpheart.00778.2003
PMid:14726301
Leonessa F and Clarke R (2003). ATP binding cassette transporters and drug resistance in breast cancer. Endocr. Relat. Cancer 10: 43-73.
http://dx.doi.org/10.1677/erc.0.0100043
PMid:12653670
Leyland-Jones BR, Townsend AJ, Tu CP, Cowan KH, et al. (1991). Antineoplastic drug sensitivity of human MCF-7 breast cancer cells stably transfected with a human alpha class glutathione S-transferase gene. Cancer Res. 51: 587-594.
PMid:1985777
Lizard-Nacol S, Coudert B, Colosetti P, Riedinger JM, et al. (1999). Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer. Breast Cancer Res. 1: 81-87.
http://dx.doi.org/10.1186/bcr17
PMid:11056682 PMCid:13914
McIlwain CC, Townsend DM and Tew KD (2006). Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25: 1639-1648.
http://dx.doi.org/10.1038/sj.onc.1209373
PMid:16550164
Morrow CS, Smitherman PK, Diah SK, Schneider E, et al. (1998). Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. J. Biol. Chem. 273: 20114-20120.
http://dx.doi.org/10.1074/jbc.273.32.20114
PMid:9685354
Moscow JA, Townsend AJ and Cowan KH (1989). Elevation of pi class glutathione S-transferase activity in human breast cancer cells by transfection of the GSTpi gene and its effect on sensitivity to toxins. Mol. Pharmacol. 36: 22-28.
PMid:2747627
Naoe T, Tagawa Y, Kiyoi H, Kodera Y, et al. (2002). Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy. Leukemia 16: 203-208.
http://dx.doi.org/10.1038/sj.leu.2402361
PMid:11840286
O'Brien ML and Tew KD (1996). Glutathione and related enzymes in multidrug resistance. Eur. J. Cancer 32: 967-978.
http://dx.doi.org/10.1016/0959-8049(96)00051-2
O'Brien M, Kruh GD and Tew KD (2000). The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J. Pharmacol. Exp. Ther. 294: 480-487.
PMid:10900222
Pakunlu RI, Cook TJ and Minko T (2003). Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharm. Res. 20: 351-359.
http://dx.doi.org/10.1023/A:1022687617318
PMid:12669953
Parkin DM, Bray F, Ferlay J and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74-108.
http://dx.doi.org/10.3322/canjclin.55.2.74
PMid:15761078
Paumi CM, Ledford BG, Smitherman PK, Townsend AJ, et al. (2001). Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. J. Biol. Chem. 276: 7952-7956.
http://dx.doi.org/10.1074/jbc.M009400200
PMid:11115505
Riddick DS, Lee C, Ramji S, Chinje EC, et al. (2005). Cancer chemotherapy and drug metabolism. Drug Metab. Dispos. 33: 1083-1096.
http://dx.doi.org/10.1124/dmd.105.004374
PMid:16049130
Rodrigues FF, Santos RE, Melo MB, Silva MA, et al. (2008). Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. Genet. Mol. Res. 7: 177-183.
http://dx.doi.org/10.4238/vol7-1gmr400
PMid:18393221
Russo A and Mitchell JB (1985). Potentiation and protection of doxorubicin cytotoxicity by cellular glutathione modulation. Cancer Treat. Rep. 69: 1293-1296.
PMid:4092192
Schisselbauer JC, Silber R, Papadopoulos E, Abrams K, et al. (1990). Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients. Cancer Res. 50: 3562-3568.
PMid:2340505
Shea TC, Claflin G, Comstock KE, Sanderson BJ, et al. (1990). Glutathione transferase activity and isoenzyme composition in primary human breast cancers. Cancer Res. 50: 6848-6853.
PMid:2208151
Tew KD (1994). Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54: 4313-4320.
PMid:8044778
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92: 205-216.
http://dx.doi.org/10.1093/jnci/92.3.205
PMid:10655437
Townsend AJ and Cowan KH (1989). Glutathione S-transferases and antineoplastic drug resistance. Cancer Bull. 41: 31-36
Townsend D and Tew K (2003a). Cancer drugs, genetic variation and the glutathione-S-transferase gene family. Am. J. Pharmacogenomics 3: 157-172.
http://dx.doi.org/10.2165/00129785-200303030-00002
PMid:12814324
Townsend DM and Tew KD (2003b). The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22: 7369-7375.
http://dx.doi.org/10.1038/sj.onc.1206940
PMid:14576844
Wilson MH, Grant PJ, Hardie LJ and Wild CP (2000). Glutathione S-transferase M1 null genotype is associated with a decreased risk of myocardial infarction. FASEB J. 14: 791-796.
PMid:10744635
Yang G, Shu XO, Ruan ZX, Cai QY, et al. (2005). Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 103: 52-58.
http://dx.doi.org/10.1002/cncr.20729
PMid:15565566